Evoke Pharma Inc (EVOK)
0.465
-0.02
(-4.22%)
USD |
NASDAQ |
May 06, 15:16
Evoke Pharma Net Income (Quarterly): -1.987M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.987M |
| September 30, 2023 | -1.694M |
| June 30, 2023 | -1.868M |
| March 31, 2023 | -2.243M |
| December 31, 2022 | -1.803M |
| September 30, 2022 | -2.014M |
| June 30, 2022 | -2.233M |
| March 31, 2022 | -2.174M |
| December 31, 2021 | -1.672M |
| September 30, 2021 | -1.970M |
| June 30, 2021 | -2.291M |
| March 31, 2021 | -2.606M |
| December 31, 2020 | -2.268M |
| September 30, 2020 | -2.129M |
| June 30, 2020 | -6.967M |
| March 31, 2020 | -1.790M |
| December 31, 2019 | -1.418M |
| September 30, 2019 | -1.628M |
| June 30, 2019 | -2.114M |
| March 31, 2019 | -1.965M |
| December 31, 2018 | -1.761M |
| September 30, 2018 | -1.520M |
| June 30, 2018 | -2.303M |
| March 31, 2018 | -1.983M |
| Date | Value |
|---|---|
| December 31, 2017 | -0.3084M |
| September 30, 2017 | -5.243M |
| June 30, 2017 | -1.626M |
| March 31, 2017 | -5.052M |
| December 31, 2016 | -1.527M |
| September 30, 2016 | -3.025M |
| June 30, 2016 | -2.970M |
| March 31, 2016 | -3.225M |
| December 31, 2015 | -2.624M |
| September 30, 2015 | -2.735M |
| June 30, 2015 | -3.241M |
| March 31, 2015 | -3.521M |
| December 31, 2014 | -2.920M |
| September 30, 2014 | -3.825M |
| June 30, 2014 | -3.547M |
| March 31, 2014 | -2.956M |
| December 31, 2013 | -1.617M |
| September 30, 2013 | -0.4859M |
| June 30, 2013 | -0.2399M |
| March 31, 2013 | -0.494M |
| December 31, 2012 | -0.6724M |
| September 30, 2012 | -0.4863M |
| June 30, 2012 | -0.3587M |
| March 31, 2012 | -0.5002M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-6.967M
Minimum
Jun 2020
-1.418M
Maximum
Dec 2019
-2.256M
Average
-2.014M
Median
Sep 2022
Net Income (Quarterly) Benchmarks
| Eton Pharmaceuticals Inc | -2.256M |
| NovaBay Pharmaceuticals Inc | -4.108M |
| Palatin Technologies Inc | -7.844M |
| iBio Inc | -8.211M |
| Theriva Biologics Inc | -5.485M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.676M |
| Total Expenses (Quarterly) | 3.564M |
| EPS Diluted (Quarterly) | -0.59 |
| Enterprise Value | 4.376M |
| Gross Profit Margin (Quarterly) | 96.48% |
| Profit Margin (Quarterly) | -118.6% |
| Earnings Yield | -501.1% |
| Normalized Earnings Yield | -501.08 |